Literature DB >> 1377101

Suppressive effect of polyoxometalates on the cytopathogenicity of human immunodeficiency virus type 1 (HIV-1) in vitro and their inhibitory activity against HIV-1 reverse transcriptase.

Y Inouye1, Y Tokutake, J Kunihara, T Yoshida, T Yamase, A Nakata, S Nakamura.   

Abstract

One isopolyoxometalate and 42 heteropolyoxometalates consisting of 3 compounds with the trivacant Keggin structure, 2 with the lacunary Keggin structure, 30 with the Keggin structure, one with the Wells-Dawson structure and 6 with miscellaneous structures were tested for their suppressive effect on the cytopathogenicity of human immunodeficiency virus type 1 (HIV-1) in vitro and inhibitory activity against HIV-1 reverse transcriptase. In contrast to the leading interpretations which attribute the suppressive effect of polyoxometalates on the cytopathogenicity of HIV-1 to the inhibition of HIV-1 reverse transcriptase by these compounds, there was no distinct correlation observed between these two functions of polyoxometalates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377101     DOI: 10.1248/cpb.40.805

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  9 in total

1.  The antibacterial activity of polyoxometalates: structures, antibiotic effects and future perspectives.

Authors:  Aleksandar Bijelic; Manuel Aureliano; Annette Rompel
Journal:  Chem Commun (Camb)       Date:  2018-01-31       Impact factor: 6.222

2.  HIV-1 protease inhibition potential of functionalized polyoxometalates.

Authors:  Andreas Flütsch; Thilo Schroeder; Markus G Grütter; Greta R Patzke
Journal:  Bioorg Med Chem Lett       Date:  2010-12-25       Impact factor: 2.823

3.  Studies on the interactions of Ti-containing polyoxometalates (POMs) with SARS-CoV 3CLpro by molecular modeling.

Authors:  Donghua Hu; Chen Shao; Wei Guan; Zhongmin Su; Jiazhong Sun
Journal:  J Inorg Biochem       Date:  2006-09-05       Impact factor: 4.155

4.  Metallodrug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain-like Protease PLpro.

Authors:  Maria Gil-Moles; Sebastian Türck; Uttara Basu; Andrea Pettenuzzo; Saurav Bhattacharya; Ananthu Rajan; Xiang Ma; Rolf Büssing; Jessica Wölker; Hilke Burmeister; Henrik Hoffmeister; Pia Schneeberg; Andre Prause; Petra Lippmann; Josephine Kusi-Nimarko; Storm Hassell-Hart; Andrew McGown; Daniel Guest; Yan Lin; Anna Notaro; Robin Vinck; Johannes Karges; Kevin Cariou; Kun Peng; Xue Qin; Xing Wang; Joanna Skiba; Łukasz Szczupak; Konrad Kowalski; Ulrich Schatzschneider; Catherine Hemmert; Heinz Gornitzka; Elena R Milaeva; Alexey A Nazarov; Gilles Gasser; John Spencer; Luca Ronconi; Ulrich Kortz; Jindrich Cinatl; Denisa Bojkova; Ingo Ott
Journal:  Chemistry       Date:  2021-11-23       Impact factor: 5.020

5.  Can polyoxometalates (POMs) prevent of coronavirus 2019-nCoV cell entry? Interaction of POMs with TMPRSS2 and spike receptor domain complexed with ACE2 (ACE2-RBD): Virtual screening approaches.

Authors:  Nahid Shahabadi; Mohammad Mahdavi; Saba Zendehcheshm
Journal:  Inform Med Unlocked       Date:  2022-03-05

Review 6.  Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.

Authors:  Zukile Mbita; Rodney Hull; Zodwa Dlamini
Journal:  Viruses       Date:  2014-08-19       Impact factor: 5.048

7.  Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate.

Authors:  Xiaoli Wang; Jiao Wang; Wenmei Zhang; Boye Li; Ying Zhu; Qin Hu; Yishu Yang; Xiaoguang Zhang; Hong Yan; Yi Zeng
Journal:  Viruses       Date:  2018-05-16       Impact factor: 5.048

Review 8.  Polyoxometalates active against tumors, viruses, and bacteria.

Authors:  Toshihiro Yamase
Journal:  Prog Mol Subcell Biol       Date:  2013

Review 9.  The use of polyoxometalates in protein crystallography - An attempt to widen a well-known bottleneck.

Authors:  Aleksandar Bijelic; Annette Rompel
Journal:  Coord Chem Rev       Date:  2015-09-01       Impact factor: 22.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.